New drug targets rare cancer mutation in early trial
NCT ID NCT02381886
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a drug called IDH305 in people with advanced cancers that have a specific IDH1R132 mutation. The main goal is to find a safe dose and see if the drug can shrink tumors. About 166 participants will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IDH305
- What this could lead to
- If it works, this could point toward a treatment for certain cancers with an IDH1 mutation.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not work or could have serious side effects. It is only for people with a specific genetic mutation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES THAT HARBOR IDHR132 MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Columbia University Medical Center- New York Presbyterian Onc Dept.
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute SC (1)
Boston, Massachusetts, 02115, United States
-
ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55
Rotterdam, 3075 EA, Netherlands
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Parkville, Victoria, 3050, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Rotterdam, South Holland, 3015 GD, Netherlands
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States